A part of Watch Media

MedWatchSaturday4 February 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
04/08/2022at 14:41

Eli Lilly downgrades after underwhelming report, though diabetes business advances

The US-based pharmaceutical firm has adjusted its earnings per share forecast following a quarter with fewer sales than analysts had expected.
Photo: VINCENT KESSLER/REUTERS / X00403
by marketwire, translated by daniel pedersen

On Thursday, Eli Lilly publicized its second quarter figures for 2022 alongside a guidance downgrade containing a revised expectation for its earnings per share to USD 7.9–8.05 from a previous USD 8.15–8.3.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Photo: MIKE SEGAR/REUTERS / X90033

    Eli Lilly squares up to Novo Nordisk on obesity market

    For subscribers

  • Photo: Novo Nordisk / PR

    Novo Nordisk upgrades despite sales and bottom line disappointments in Q2

    For subscribers

  • Photo: Novo Nordisk / PR

    Investors' speedy study hopes quashed as Novo Nordisk continues cardiovascular trial

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Nu mangler kun en endelig vedtagelse i EU-Parlamentet, før lovforslag om at udskyde deadlines for nye krav til medicinsk udstyr. er en realitet. | Foto: Thomas Borberg/Ritzau Scanpix
Medtech

Another hurdle overcome in delaying MDR deadline

EU member countries have voted unanimously to adopt an EU Commission proposal to stagger the implementation of the new Medical Device Regulation. Now, only the EU Parliament’s vote remains. 
  • Asensus Surgical wins CE Mark for intelligent surgical unit under MDR rules
  • EU Commission to give more time for MDR transition

For subscribers

Foto: Stine Tidsvilde
Pharma & biotech

Novo Nordisk hopes to retain employees with share gift

For subscribers

Luja can potentially solve a long-lived UTI problem for people who need help with bladder control issues by using new micro-hole technology
Medtech

Coloplast to set new treatment standard with Luja – but keeps sales goal under wraps

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

Foto: Coloplast/pr
Medtech

Coloplast launches male catheter featuring new technology

For subscribers

Foto: Coloplast / Pr
Medtech

Coloplast's bottom line disappoints in otherwise strong report

For subscribers

Further reading

Foto: Mike Segar/Reuters/Ritzau Scanpix
Pharma & biotech

Eli Lilly predicts possible launch of obesity drug in 2023

The US-based company hopes to launch Wegovy-competitor tirzepatide for obesity this year or early next year.

For subscribers

Foto: Mike Blake/Reuters/Ritzau Scanpix
Pharma & biotech

Eli Lilly raises 2023 expectations

A new forecasted tax rate for the fiscal year to come means Lilly can upgrade some expectations, reveals the company’s fourth-quarter report.

For subscribers

Pharma & biotech

GlobalData predicts huge diabetes market growth, names Novo Nordisk drugs as drivers

The type 2 diabetes treatment market will triple in size over ten years, according to the analysis firm’s estimations.

For subscribers

Latest news

  • Top news from MedWatch this week – 3 Feb
  • Coloplast to set new treatment standard with Luja – but keeps sales goal under wraps – 3 Feb
  • China accepts regulatory filing for ALK allergy tablet – 3 Feb
  • Another hurdle overcome in delaying MDR deadline – 3 Feb
  • Dupixent becomes ninefold blockbuster – 3 Feb
  • ALK forecasts lower growth in 2023 than strong 2022 result – 3 Feb
  • Unilabs and Siemens Healthineers enter million-euro strategic partnership – 3 Feb
  • Coloplast launches male catheter featuring new technology – 3 Feb
  • Novo Nordisk hopes to retain employees with share gift – 3 Feb
  • Coloplast's bottom line disappoints in otherwise strong report – 3 Feb
See all

Jobs

  • Lead Data Architect

  • Regulatory Affairs Professional

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Commercial Director

  • Application Manager

  • Sr. Director, Drug Safety Physician

  • Senior Health Economics and Outcomes Research (HEOR) Manager

  • Clinical Operational Associate

  • Medical Advisor (Metabolism)

  • Senior Clinical Project Manager

  • Application Manager

  • Supply Chain Manager

  • Experienced Patent Counsel

See all jobs

Jobs

  • Lead Data Architect

  • Regulatory Affairs Professional

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Commercial Director

  • Application Manager

  • Sr. Director, Drug Safety Physician

  • Senior Health Economics and Outcomes Research (HEOR) Manager

  • Clinical Operational Associate

  • Medical Advisor (Metabolism)

  • Senior Clinical Project Manager

  • Application Manager

  • Supply Chain Manager

  • Experienced Patent Counsel

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge